Help
RSS
API
Feed
Maltego
Contact
Domain > dev-trials-api.montefioreeinstein.org
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2025-06-05
34.233.88.95
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: nginxDate: Tue, 27 May 2025 08:13:03 GMTContent-Type: text/html; charsetiso-8859-1Content-Length: 254X-Content-Type-Options: nosniffLocation: https://dev-trials-api.montefioreeinstein.org/Cache-Control: max-age31536000Expires: Wed, 27 May 2026 08:13:03 GMTX-Request-ID: v-694acd70-3ad2-11f0-a63d-334e6234e7f5Age: 793337Via: varnishX-Cache: HITX-Cache-Hits: 15Connection: keep-alive !DOCTYPE HTML PUBLIC -//IETF//DTD HTML 2.0//EN>html>head>title>301 Moved Permanently/title>/head>body>h1>Moved Permanently/h1>p>The document has moved a hrefhttps://dev-trials-api.montefioreeinstein.org/>here/a>./p>/body>/html>
Port 443
HTTP/1.1 200 OKServer: nginxDate: Thu, 05 Jun 2025 12:35:22 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveCache-Control: must-revalidate, no-cache, privateX-Drupal-Dynamic-Cache: MISSContent-language: enX-Content-Type-Options: nosniffX-Frame-Options: SAMEORIGINExpires: Sun, 19 Nov 1978 05:00:00 GMTX-Generator: Drupal 10 (https://www.drupal.org)Access-Control-Allow-Headers: *Access-Control-Allow-Methods: GETAccess-Control-Expose-Headers: falseAccess-Control-Allow-Credentials: trueAccess-Control-Allow-Origin: *Content-Security-Policy: script-src self unsafe-eval unsafe-inline *.fontawesome.com *.jsdelivr.net *.googleapis.com *.jquery.com *.vimeo.com *.cookielaw.org *.vimeocdn.com *.airbud.io unpkg.com:* *.cloudflare.com intermezzo-coop.eu:* *.google.com *.montefioreeinstein.org *.localizejs.com ; upgrade-insecure-requestsX-Content-Security-Policy: script-src self unsafe-eval unsafe-inline *.fontawesome.com *.jsdelivr.net *.googleapis.com *.jquery.com *.vimeo.com *.cookielaw.org *.vimeocdn.com *.airbud.io unpkg.com:* *.cloudflare.com intermezzo-coop.eu:* *.google.com *.montefioreeinstein.org *.localizejs.com ; upgrade-insecure-requestsX-WebKit-CSP: script-src self unsafe-eval unsafe-inline *.fontawesome.com *.jsdelivr.net *.googleapis.com *.jquery.com *.vimeo.com *.cookielaw.org *.vimeocdn.com *.airbud.io unpkg.com:* *.cloudflare.com intermezzo-coop.eu:* *.google.com *.montefioreeinstein.org *.localizejs.com ; upgrade-insecure-requestsStrict-Transport-Security: max-age1000; includeSubDomainsX-Drupal-Cache: MISSVary: Accept-EncodingX-Request-ID: v-8ba6a70c-4209-11f0-bfc9-138e28363a5eX-AH-Environment: devAge: 0Via: varnishX-Cache: MISSAccept-Ranges: bytes !DOCTYPE html>html langen dirltr prefixcontent: http://purl.org/rss/1.0/modules/content/ dc: http://purl.org/dc/terms/ foaf: http://xmlns.com/foaf/0.1/ og: http://ogp.me/ns# rdfs: http://www.w3.org/2000/01/rdf-schema# schema: http://schema.org/ sioc: http://rdfs.org/sioc/ns# sioct: http://rdfs.org/sioc/types# skos: http://www.w3.org/2004/02/skos/core# xsd: http://www.w3.org/2001/XMLSchema# > head> meta charsetutf-8 />meta nameGenerator contentDrupal 10 (https://www.drupal.org) />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />noscript>link relstylesheet href/core/themes/claro/css/components/dropbutton-noscript.css?svhl1f />/noscript>link relicon href/core/misc/favicon.ico typeimage/vnd.microsoft.icon />link relalternate typeapplication/rss+xml title hrefhttps://dev-trials-api.montefioreeinstein.org/rss.xml /> title>Home | Drush Site-Install/title> link relstylesheet mediaall href/sites/default/files/css/css_3qZFoeVSueaUzF3MypVCCh8OqTGelDreQxvPB5hlmOs.css?delta0&languageen&themeclaro&includeeJxLzi9K1c_LL8pNzMmsStVJzkksytdPz8lPSszRLS6pzMnMS9cpy0wtL9YHk3q5-SmlOTB1QLK4uFIvLz8lFQD_aRv4 />link relstylesheet mediaall href/sites/default/files/css/css_SBS1vWP8WQcbtadcfjc9QhTgKGZE1pq16t0DLoblANw.css?delta1&languageen&themeclaro&includeeJxLzi9K1c_LL8pNzMmsStVJzkksytdPz8lPSszRLS6pzMnMS9cpy0wtL9YHk3q5-SmlOTB1QLK4uFIvLz8lFQD_aRv4 /> script src/sites/default/files/js/js_13m1Iwr8OgEfcHmb3M6Ie1Xht3kdFFXLHbo3obRjv7U.js?scopeheader&delta0&languageen&themeclaro&includeeJxLzi9K1U8pKi1IzNHLTS0uTkxP1UkGiWUVlqYWVULYUPmS_NLkjNSy1LySYt2S1OISAMQKF3c>/script> /head> body classpath-frontpage> a href#main-content classvisually-hidden focusable skip-link> Skip to main content /a> div classpage-wrapper dialog-off-canvas-main-canvas data-off-canvas-main-canvas> main> div classvisually-hidden>a idmain-content tabindex-1>/a>/div> header classcontent-header clearfix> div classlayout-container> div classregion region-breadcrumb> /div> div classregion region-header> div idblock-claro-page-title classblock block-core block-page-title-block> h1 classpage-title>/h1> /div> /div> /div> /header> div classlayout-container> div classpage-content clearfix> div classregion region-highlighted> div data-drupal-messages-fallback classhidden messages-list>/div> /div> div classhelp> /div> div classregion region-content> div idblock-claro-content classblock block-system block-system-main-block> div classviews-element-container>div classview view-frontpage view-id-frontpage view-display-id-page_1 js-view-dom-id-ddd1f01312a9d69d8862f6411f96fa90abd21e72817ec4fb35ab4f41670a7b63> div classview-content> div classviews-row>article data-history-node-id412916 about/node/412916 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412916 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-23T15:42:14+00:00 titleWednesday, October 23, 2024 - 15:42 classdatetime>Wed, 10/23/2024 - 15:42/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412916 reltag titleTesting Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain hreflangen>Read morespan classvisually-hidden> about Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412911 about/node/412911 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412911 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-23T15:42:12+00:00 titleWednesday, October 23, 2024 - 15:42 classdatetime>Wed, 10/23/2024 - 15:42/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412911 reltag titleSelf-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) hreflangen>Read morespan classvisually-hidden> about Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412906 about/node/412906 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412906 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-23T15:42:10+00:00 titleWednesday, October 23, 2024 - 15:42 classdatetime>Wed, 10/23/2024 - 15:42/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412906 reltag titleSafety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism hreflangen>Read morespan classvisually-hidden> about Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412901 about/node/412901 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412901 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-23T15:41:32+00:00 titleWednesday, October 23, 2024 - 15:41 classdatetime>Wed, 10/23/2024 - 15:41/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412901 reltag titleEfficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) hreflangen>Read morespan classvisually-hidden> about Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412896 about/node/412896 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412896 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-23T15:40:40+00:00 titleWednesday, October 23, 2024 - 15:40 classdatetime>Wed, 10/23/2024 - 15:40/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412896 reltag titleStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) hreflangen>Read morespan classvisually-hidden> about Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412181 about/node/412181 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412181 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-14T16:44:31+00:00 titleMonday, October 14, 2024 - 16:44 classdatetime>Mon, 10/14/2024 - 16:44/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412181 reltag titleSafety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF hreflangen>Read morespan classvisually-hidden> about Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412176 about/node/412176 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412176 relbookmark>span classfield field--name-title field--type-string field--label-hidden>A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-14T16:44:23+00:00 titleMonday, October 14, 2024 - 16:44 classdatetime>Mon, 10/14/2024 - 16:44/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412176 reltag titleA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients hreflangen>Read morespan classvisually-hidden> about A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412171 about/node/412171 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412171 relbookmark>span classfield field--name-title field--type-string field--label-hidden>A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-14T16:44:20+00:00 titleMonday, October 14, 2024 - 16:44 classdatetime>Mon, 10/14/2024 - 16:44/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412171 reltag titleA Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors hreflangen>Read morespan classvisually-hidden> about A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412166 about/node/412166 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412166 relbookmark>span classfield field--name-title field--type-string field--label-hidden>A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-14T16:44:09+00:00 titleMonday, October 14, 2024 - 16:44 classdatetime>Mon, 10/14/2024 - 16:44/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412166 reltag titleA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer hreflangen>Read morespan classvisually-hidden> about A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer/span>/a>/li>/ul> /div> /div>/article>/div> div classviews-row>article data-history-node-id412161 about/node/412161 classnode node--type-clinical-trial node--promoted node--view-mode-teaser> h2> a href/node/412161 relbookmark>span classfield field--name-title field--type-string field--label-hidden>Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)/span>/a> /h2> footer classnode__meta> article typeofschema:Person about/user/211 classprofile> /article> div classnode__submitted> Submitted by span classfield field--name-uid field--type-entity-reference field--label-hidden>span lang about/user/211 typeofschema:Person propertyschema:name datatype>kassing/span>/span> on span classfield field--name-created field--type-created field--label-hidden>time datetime2024-10-14T16:43:46+00:00 titleMonday, October 14, 2024 - 16:43 classdatetime>Mon, 10/14/2024 - 16:43/time>/span> /div> /footer> div classnode__content> div classnode__links> ul classlinks inline>li classnode-readmore>a href/node/412161 reltag titleZibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) hreflangen>Read morespan classvisually-hidden> about Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)/span>/a>/li>/ul> /div> /div>/article>/div> /div> nav classpager rolenavigation aria-labelledbypagination-heading> h4 idpagination-heading classvisually-hidden>Pagination/h4> ul classpager__items js-pager__items> li classpager__item pager__item--active pager__item--number>a href?page0 titleCurrent page aria-currentpage classpager__link is-active>span classvisually-hidden> Page /span> 1 /a>/li> li classpager__item pager__item--number>a href?page1 titleGo to page 2 classpager__link>span classvisually-hidden> Page /span> 2 /a>/li> li classpager__item pager__item--number>a href?page2 titleGo to page 3 classpager__link>span classvisually-hidden> Page /span> 3 /a>/li> li classpager__item pager__item--number>a href?page3 titleGo to page 4 classpager__link>span classvisually-hidden> Page /span> 4 /a>/li> li classpager__item pager__item--number>a href?page4 titleGo to page 5 classpager__link>span classvisually-hidden> Page /span> 5 /a>/li> li classpager__item pager__item--number>a href?page5 titleGo to page 6 classpager__link>span classvisually-hidden> Page /span> 6 /a>/li> li classpager__item pager__item--number>a href?page6 titleGo to page 7 classpager__link>span classvisually-hidden> Page /span> 7 /a>/li> li classpager__item pager__item--number>a href?page7 titleGo to page 8 classpager__link>span classvisually-hidden> Page /span> 8 /a>/li> li classpager__item pager__item--number>a href?page8 titleGo to page 9 classpager__link>span classvisually-hidden> Page /span> 9 /a>/li> li classpager__item pager__item--ellipsis rolepresentation>…/li> li classpager__item pager__item--action pager__item--next>a href?page1 titleGo to next page relnext classpager__link pager__link--action-link>span classvisually-hidden>Next page/span>span classpager__item-title pager__item-title--forward aria-hiddentrue> Next /span>/a>/li> li classpager__item pager__item--action pager__item--last>a href?page258 titleGo to last page classpager__link pager__link--action-link>span classvisually-hidden>Last page/span>span classpager__item-title pager__item-title--forward aria-hiddentrue> Last /span>/a>/li> /ul> /nav> div classfeed-icons> a hrefhttps://dev-trials-api.montefioreeinstein.org/rss.xml classfeed-icon> Subscribe to /a> /div> /div>/div> /div> /div> /div> /div> /main> /div> script typeapplication/json data-drupal-selectordrupal-settings-json>{path:{baseUrl:\/,pathPrefix:,currentPath:node,currentPathIsAdmin:false,isFront:true,currentLanguage:en},pluralDelimiter:\u0003,suppressDeprecationErrors:true,user:{uid:0,permissionsHash:5be7a6116e636e6c89d6f4c25446ec707941d145662a34f58dd0b53f71b1968b}}/script>script src/sites/default/files/js/js_bfM82na6N8sVeL56SZAFikdfoqAuOUudXEX30cXIU7M.js?scopefooter&delta0&languageen&themeclaro&includeeJxLzi9K1U8pKi1IzNHLTS0uTkxP1UkGiWUVlqYWVULYUPmS_NLkjNSy1LySYt2S1OISAMQKF3c>/script> /body>/html>
Subdomains
Date
Domain
IP
qa.montefioreeinstein.org
2025-04-26
34.233.88.95
stage.montefioreeinstein.org
2024-11-24
23.41.4.80
search-api.montefioreeinstein.org
2025-01-20
23.59.88.202
qa-search-api.montefioreeinstein.org
2025-06-05
34.233.88.95
stage-search-api.montefioreeinstein.org
2025-05-28
34.233.88.95
uat-search-api.montefioreeinstein.org
2025-01-20
34.233.88.95
dev-search-api.montefioreeinstein.org
2025-04-22
34.233.88.95
dev-trials-api.montefioreeinstein.org
2025-06-05
34.233.88.95
qa-supplychain.montefioreeinstein.org
2025-05-17
34.233.88.95
origin.montefioreeinstein.org
2025-04-29
34.233.88.95
stage-origin.montefioreeinstein.org
2025-05-14
34.233.88.95
search-admin.montefioreeinstein.org
2025-05-06
34.233.88.95
qa-search-admin.montefioreeinstein.org
2025-04-20
34.233.88.95
stage-search-admin.montefioreeinstein.org
2025-05-15
34.233.88.95
uat-search-admin.montefioreeinstein.org
2025-04-21
34.233.88.95
dev-search-admin.montefioreeinstein.org
2025-01-20
34.233.88.95
assets.montefioreeinstein.org
2024-01-11
23.192.230.149
uat.montefioreeinstein.org
2025-05-18
34.233.88.95
assets-alt.montefioreeinstein.org
2024-08-04
23.41.4.81
content.montefioreeinstein.org
2025-05-13
34.233.88.95
qa-content.montefioreeinstein.org
2025-05-11
34.233.88.95
stage-content.montefioreeinstein.org
2025-04-25
34.233.88.95
uat-content.montefioreeinstein.org
2025-04-21
34.233.88.95
dev-content.montefioreeinstein.org
2025-04-21
34.233.88.95
dev.montefioreeinstein.org
2025-05-14
34.233.88.95
www.montefioreeinstein.org
2025-01-18
23.41.4.80
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]